Cocrystal pharma highlights progress with cc-42344 as a potential oral treatment for pandemic and seasonal influenza a at the world antiviral congress 2022

Affirms plans to report topline p hase 1 results in 2022 and to initiate p hase 2a influenza human challenge trial in 2023
COCP Ratings Summary
COCP Quant Ranking